Overweight and obesity

Obesity is defined as an excessive accumulation of body fat beyond normal levels that is associated with health risks.¹

  • The body mass index (BMI) is ≥ 30 kg/m² of body surface area.

  • Pre‑obesity is defined as a BMI of 25.0–29.9 kg/m².

  • Overweight is defined as a BMI of ≥ 25.0 kg/m².

Obesity is defined as an excessive accumulation of body fat beyond normal levels that is associated with health risks.¹

  • The body mass index (BMI) is ≥ 30 kg/m² of body surface area.

  • Pre‑obesity is defined as a BMI of 25.0–29.9 kg/m².

  • Overweight is defined as a BMI of ≥ 25.0 kg/m².

OVERWEIGHT AND OBESITY

Obesity is defined as an excessive accumulation of body fat beyond normal levels that is associated with health risks.¹
  • The body mass index (BMI) is ≥ 30 kg/m² of body surface area.
     
  • Pre‑obesity is defined as a BMI of 25.0–29.9 kg/m².
     
  • Overweight is defined as a BMI of ≥ 25.0 kg/m².
Overall, in Germany:2

19%

of all men and women are affected by obesity.

27.6%

of women

are overweight
(without obesity).

41.3%

of men

are overweight (without obesity).

1

The number of people who are overweight or obese has increased in recent years. The main reasons are thought to be changes in dietary behaviour and a widespread lack of physical activity.1

Overall, in Germany:2

19%

of all men and women are affected by obesity.

27.6%

of women

are overweight (without obesity).

41.3%

of men

are overweight
(without obesity).

1

The number of people who are overweight or obese has increased in recent years. The main reasons are thought to be changes in dietary behaviour and a widespread lack of physical activity.¹

Possible causes of obesity

The following factors may contribute to overweight (in alphabetical order):¹
The following factors may contribute to overweight (in alphabetical order):¹

  • Chronic stress 

  • Depressive disorders; eating disorders 
    (e.g. binge‑eating disorder [BED], night‑eating disorder)

  • Endocrine disorders  
    (e.g. hypothyroidism, Cushing’s syndrome)

  • Excessive energy intake
    due to constant availability and a wide range of energy‑dense and highly processed foods and beverages

  • Familial predisposition, genetic causes
     

  • Lack of physical activity 
    predominantly sedentary occupations

  • Medications
    (e.g. antidepressants, antipsychotics, antiepileptics, certain antidiabetic drugs, glucocorticoids, some contraceptives, beta‑blockers)

  • Other causes
    (e.g. excessive weight gain during pregnancy, smoking cessation)

     

Therapy FOR overweight and obesity

If the following criteria are met, an indication for therapy in cases of overweight or obesity is present:¹

BMI ≥ 30 kg/m² or

Overweight with a BMI between 25 and < 30 kg/m² and the simultaneous presence of overweight‑related health disorders (e.g. hypertension, type 2 diabetes mellitus), or

  • Predominantly abdominal fat distribution (waist circumference ≥ 102 cm in men or ≥ 88 cm in women), or

  • Diseases that are exacerbated by overweight, or

  • A high level of psychosocial distress

The goal of weight reduction is the long‑term reduction of body weight, associated with a decrease in weight‑related risks and comorbidities, prevention of work disability and premature retirement, and an improvement in quality of life.¹

Basic therapy

Basic therapy

The foundation of all weight management is a basic therapy consisting of dietary modification, increased physical activity and behavioural change. The design of this basic therapy depends, among other factors, on the severity of overweight or obesity.¹ formoline L112 EXTRA provides support during basic therapy.3

The foundation of all weight management is a basic therapy consisting of dietary modification, increased physical activity and behavioural change. The design of this basic therapy depends, among other factors, on the severity of overweight or obesity.¹ formoline L112 EXTRA provides support during basic therapy.3

Nutrition therapy
Nutrition therapy

Nutrition therapy focuses on reducing overall energy intake. For long‑term weight reduction, a sustained lower‑energy diet is required. A daily energy deficit of about 500–600 kcal, or an individually determined deficit, is recommended. Highly restrictive or one‑sided diets should be avoided.

Hilfe bei der Umsetzung von Verhaltensänderungen und der Einnahme von formoline L112 EXTRA bietet die My-formoline Begleit-App.

Physical activity therapy
Physical activity therapy

Physical activity therapy encourages people with overweight or obesity to increase their daily and leisure‑time physical activity. Goals should be realistic and easy to understand.

Hilfe bei der Umsetzung von Verhaltensänderungen und der Einnahme von formoline L112 EXTRA bietet die My-formoline Begleit-App.

Behavioural changes
Behavioural changes

Behavioural changes recommended for people with overweight and obesity include self‑monitoring of behaviours and weight‑loss progress, stimulus control, setting realistic goals, reinforcement strategies (such as rewarding positive changes), relapse prevention, strategies for dealing with weight regain and social support.

Hilfe bei der Umsetzung von Verhaltensänderungen und der Einnahme von formoline L112 EXTRA bietet die My-formoline Begleit-App.

Nutrition therapy
Nutrition therapy

Nutrition therapy focuses on reducing overall energy intake. For long‑term weight reduction, a sustained lower‑energy diet is required. A daily energy deficit of about 500–600 kcal, or an individually determined deficit, is recommended. Highly restrictive or one‑sided diets should be avoided.

Hilfe bei der Umsetzung von Verhaltensänderungen und der Einnahme von formoline L112 EXTRA bietet die My-formoline Begleit-App.

Physical activity therapy
Physical activity therapy

Physical activity therapy encourages people with overweight or obesity to increase their daily and leisure‑time physical activity. Goals should be realistic and easy to understand.

Hilfe bei der Umsetzung von Verhaltensänderungen und der Einnahme von formoline L112 EXTRA bietet die My-formoline Begleit-App.

Behavioural changes
Behavioural changes

Behavioural changes recommended for people with overweight and obesity include self‑monitoring of behaviours and weight‑loss progress, stimulus control, setting realistic goals, reinforcement strategies (such as rewarding positive changes), relapse prevention, strategies for dealing with weight regain and social support.

Hilfe bei der Umsetzung von Verhaltensänderungen und der Einnahme von formoline L112 EXTRA bietet die My-formoline Begleit-App.

Pharmacological therapy

If significant and sustained weight reduction cannot be achieved or maintained with basic therapy alone, pharmacological treatment of obesity may be considered. In Germany, approved options currently include, among others, GLP‑1 agonists and a lipase inhibitor.1

Prerequisites for pharmacological therapy for weight reduction or for maintaining achieved weight loss are:¹

  • BMI ≥ 30 kg/m²

  • BMI ≥ 27 kg/m²
(when using a lipase inhibitor: BMI ≥ 28 kg/m²) and the presence of obesity‑associated risk factors and/or comorbidities, or

Pharmacological therapy should always be carried out in combination with a multimodal basic therapy.1

formoline L112 EXTRA

Think beyond weight‑loss injections with us – to support your patients holistically in weight management.

Think beyond weight‑loss injections with us – to support your patients holistically in weight management.

Why formoline L112 EXTRA?

  • Post‑GLP‑1: helps counteract the yo‑yo effect

  • More cost‑effective for long‑term use

  • No injections required (oral administration)3

  • Pre‑GLP‑1: suitable as an entry therapy for patients with overweight who are undecided

  • High tolerability (purely physical mode of action, non‑systemic)3

  • Clinically relevant efficacy4

Thinking beyond GLP-1

FAQ

OVERWEIGHT

Overall, 19% of men and women in Germany are affected by obesity.2

In Germany, 27.6% of women and 41.3% of men are overweight without obesity.2

Prerequisites for pharmacological therapy for weight reduction or for maintaining achieved weight loss are:1

  • a BMI ≥ 27 kg/m² (when using a lipase inhibitor: BMI ≥ 28) together with obesity‑associated risk factors and/or comorbidities, or
  • a BMI ≥ 30 kg/m²

Practice Updates

Stay Informed

Subscribe to our Practice Update for the latest clinical updates, research findings and educational opportunities.

By subscribing, you agree to receive communications from Certmedica International GmbH. You also agree to the Privacy Policy of Certmedica International GmbH. You can unsubscribe at any time.

Thank You for Your Interest!

Your request has been successfully submitted. You will shortly receive further information about Rethinking GLP‑1 as well as current content, services and practice-relevant updates.